AstraZeneca announces FluMist Quadrivalent approved and available in Canada; Sinovac gets CFDA approval to start clinical trials of varicella vax;

> AstraZeneca ($AZN) Canada announced the approval and availability of FluMist Quadrivalent. Release

> Beijing-based Sinovac Dalian ($SVA) got approval from the China FDA to begin clinical trials of its varicella vaccine. Release

> Indian Immunologicals announced that its new $38 million facility to produce human and animal vaccines has begun operations. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.